Glucocorticoid Compounds Modify Smoothened Localization and Hedgehog Pathway Activity  by Wang, Yu et al.
Chemistry & Biology
ArticleGlucocorticoid Compounds Modify
Smoothened Localization
and Hedgehog Pathway Activity
Yu Wang,1,2,3,7 Lance Davidow,1,4 Anthony C. Arvanites,1,4 Joel Blanchard,1,4,8 Kelvin Lam,1,4,9 Ke Xu,1,4 Vatsal Oza,1,4
Jin Woo Yoo,5 Jessica M.Y. Ng,6 Tom Curran,6 Lee L. Rubin,1,4,* and Andrew P. McMahon1,2,4,10,*
1Department of Stem Cell and Regenerative Biology
2Department of Molecular and Cellular Biology
3Department of Chemistry and Chemical Biology
4Harvard Stem Cell Institute
5Harvard College
Harvard University, Cambridge, MA 02138, USA
6Children’s Hospital of Philadelphia, Philadelphia, PA 19104, USA
7Present address: The Morgridge Institute for Research, Madison, WI 53715, USA
8Present address: The Scripps Research Institute, La Jolla, CA 92037, USA
9Present address: Blue Sky Biotech, Inc., Worcester, MA 01605, USA
10Present address: Department of Stem Cells and Regenerative Medicine, University of Southern California, 1425 San Pablo Street,
Los Angeles, CA 90089, USA
*Correspondence: lee_rubin@harvard.edu (L.L.R.), amcmahon@mcb.harvard.edu (A.P.M.)
http://dx.doi.org/10.1016/j.chembiol.2012.06.012SUMMARY
TheHedgehog signalingpathway is linked to a variety
of diseases, notably a range of cancers. The first
generation of drug screens identified Smoothened
(Smo), a membrane protein essential for signaling,
as an attractive drug target. Smo localizes to the
primary cilium upon pathway activation, and this
transition is critical for the response to Hedgehog
ligands. In a high content screen directly monitoring
Smo distribution in Hedgehog-responsive cells, we
identified different glucocorticoids as specificmodu-
lators of Smo ciliary accumulation. One class pro-
moted Smo accumulation, conferring cellular hyper-
sensitivity to Hedgehog stimulation. In contrast, a
second class inhibited Smo ciliary localization and
signaling activity by both wild-type Smo, and mutant
forms of Smo, SmoM2, and SmoD473H, that are
refractory to previously identified Smo antagonists.
These findings point to the potential for developing
glucocorticoid-based pharmacological modulation
of Smo signaling to treat mutated drug-resistant
forms of Smo, an emerging problem in long-term
cancer therapy. They also raise a concern about
potential crosstalk of glucocorticoid drugs in the
Hedgehog pathway, if therapeutic administration
exceeds levels associated with on-target transcrip-
tional mechanisms of glucocorticoid action.
INTRODUCTION
The Hedgehog (Hh) pathway is one of the central pathways of
animal development, and deregulated pathway activity underlies972 Chemistry & Biology 19, 972–982, August 24, 2012 ª2012 Elsevia multitude of diseases, notably a variety of cancers (Rubin and
de Sauvage, 2006). Activating mutations in Hh pathway compo-
nents are cell intrinsic causal factors in cancers linked to Gorlin
syndrome, medulloblastoma (MB), basal cell carcinoma (BCC),
and rhabdomyosarcoma. In addition, paracrine Hh signaling-
based modulation of the tumor microenvironment is thought to
play awider role in the support of a number of othermalignancies
including those of the breast, lung, liver, stomach, pancreas,
prostate, and colon (Yauch et al., 2008). Hh signaling is also
linked to medically beneficial actions such as the promotion of
stem/progenitor cell proliferation that may enable regenerative
therapies. Considerable clinical interest has developed about
the mechanisms of Hh pathway action and the identification of
drugs that can modulate pathway activity.
Smoothened (Smo), a seven-pass transmembraneprotein, has
emerged as a predominant target in screens for small-molecule
pathway modulators. Smo is essential for all Hh signaling (Zhang
et al., 2001). All 7 drugs in clinical trials for Hh targeted cancer
therapy act directly on Smo to inhibit Hh signaling (Tremblay
et al., 2010). Among these, GDC0449 (also known as RG3616
or Vismodegib), was recently approved by the US Food and
Drug Administration (FDA) for indication of advanced BCC (Alli-
son, 2012). On the other hand, it was reported that administration
of at least two clinical Smo antagonists (GDC0449 and LDE225)
resulted in cancer relapse in human and/or mouse in part due
to emergence of drug resistant mutations of Smo, which high-
lighted an unmet medical need for next generation Smo antago-
nists that can circumvent suchmutations (Buonamici et al., 2010;
Yauch et al., 2009). Smo regulation is quite unusual. Hhbinding to
its receptor Patched-1 (Ptch1) counters Ptch1 mediated inhibi-
tion of Smo, enabling Smo-dependent activation of a Gli-based
transcriptional response (Rohatgi et al., 2007). These events
correlate with, and are critically linked to, the primary cilium
(PC), a tubulin-based cell extension present on most vertebrate
cells (Goetz and Anderson, 2010). After binding Hh, Ptch1moves
from the PC while Smo accumulates on the ciliary axoneme.er Ltd All rights reserved
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Glucocorticoid Crosstalk with Hedgehog SignalingThough themechanistic details are unclear, Smo action at the PC
is essential for pathway activation (Han et al., 2009; Wong et al.,
2009), and this cellular translocation presents an opportunity for
novel drug development.
Here, we report on a high content screen (HCS) to identify
small molecules that modulate Smo accumulation at the PC.
Most strikingly, we identified a large number of glucocorticoids
(GCs), several of which are in clinical use, that induce this
activity. Surprisingly, these compounds fail to trigger robust
pathway activation; instead, they sensitize cells to Hh ligand
input and impair pathway inhibition by coadministered pharma-
cological antagonists of Smo signaling. In contrast, another
steroid, budesonide, inhibits Smo ciliary translocation and Hh
signaling, synergizing with GDC0449, a Smo antagonist under
clinical evaluation. Importantly, budesonide acts similarly on
wild-type Smo, and mutant forms refractory to other Smo antag-
onists, SmoM2 and SmoD473H (Xie et al., 1998; Yauch et al.,
2009). These findings have important ramifications for the design
of new therapeutic approaches to treat cancers whose growth
can be modulated by Smo activation, and potential implications
for off-target crosstalk of glucocorticoid drugs in the Hedgehog
signaling pathway.
RESULTS
Development of aHCS to Identify Agonists of SmoCiliary
Accumulation
To gain a more comprehensive view of the Hh pathway at
early stages of drug development, we developed and validated
a HCS method based directly on Smo translocation to the
PC (Wang et al., 2012). Herein, we report our findings while
using the method to identify agonists of Smo ciliary accumula-
tion. An enhanced green fluorescent protein (EGFP)-tagged
form of human Smo was introduced into Hh-responsive NIH
3T3 cells (Wang et al., 2009) (Figure S1A available online) to
generate a clonal cell line in which Hh-dependent accumulation
of Smo::EGFP in the PC mirrored movement of endogenous
Smo (Wang et al., 2009). An Inversin(Ivs)::tagRFPT expression
cassette provided a constitutive, independent PCmarker (Wata-
nabe et al., 2003).
Custom algorithms were developed to perform quantitative
multiparametric image analyses (Wang et al., 2012). Robust
dose-dependent responses were observed upon treatment
with several known small molecule modulators of Smo: the
agonist SAG and the antagonist cyclopamine (Cyc), both of
which directly bind Smo, and forskolin (FKL), whose stimulatory
action on protein kinase A inhibits Smo signaling (Figures
S1A–S1F). Despite the fact that Cyc and SAG physically interact
with Smo in a competitive fashion suggesting a common binding
mechanism, and that both induce ciliary accumulation, Cyc-
bound Smo is inactive. Thus, accumulation within the primary
cilium appears to be essential but not sufficient for downstream
activation of the Hh pathway. In contrast, FKL likely induce Smo
ciliary accumulation indirectly potentially by accelerating antero-
grade intraflagellar transport (Besschetnova et al., 2010). A
better understanding awaits a clearer picture of the cellular traf-
ficking processes. As a demonstration of the assay’s ability to
detect local changes within the PC, elongation of the PC on
FKL treatment was detected as an expanded Ivs+ domain (lastChemistry & Biology 19, 97panel in Figure S1F), consistent with a recent report (Besschet-
nova et al., 2010).
Screening Results
We conducted a screen with a library consisting of 5,672
compounds with annotated activities, including FDA-approved
drugs and drug candidates in preclinical or clinical development.
Representative examples of plates including small-molecule
control wells are shown for the analysis (Figure S1G). Z-prime
scores (Zhang et al., 1999) consistently >0.4 indicate a reason-
able reliability of the primary screen.
Approximately 60 compounds in 15 distinct chemical classes
were confirmed to induce Smo accumulation at the PC, after
rigorous assessment of the dose-response curves for primary
hits. As expected, these comprised both pathway agonists and
antagonists. For example, LY 294002, an inhibitor of phosphati-
dylinositol 3-kinase (PI3K) (Vlahos et al., 1994), induces Smo
ciliary accumulation, but inhibits Hh signaling (Figures S1H–
S1K). The PI3K pathway is important in a variety of cancer types
and may intersect with the Hh pathway in tumorigenesis (Ham-
bardzumyan et al., 2008). In combination treatment, a PI3K inhib-
itor and a Smo antagonist delayed the onset of drug resistance in
a mouse model of medulloblastoma (Buonamici et al., 2010;
Dijkgraaf et al., 2011). PI3K action has also been linked to the
regulation of Gli proteins through the Akt pathway (Riobo´ et al.,
2006). These data suggest that PI3K may act at multiple levels
in Hh signaling.
Strikingly, the most predominant chemical class identified
comprised naturally occurring and synthetic GCs, several of
which are widely used as antiinflammatory agents in the clinic
(Figures 1A and 1B; Figure S1L) (Sommer and Ray, 2008). Inter-
estingly, a recent screen examining b-arrestin aggregation iden-
tified an overlap with a subset of these compounds, lending
additional support to a GC intersection in Smo-directed Hedge-
hog signaling, but also raising the possibility of alternative mech-
anisms (Wang et al., 2010). Structure-activity relationship (SAR)
analysis suggests that fluorine at position 9, a ketal at positions
16 and 17, and protonation at position 11 significantly enhance
the potency of this class of compounds in directing Smo accu-
mulation to the PC (Figure 1C).
GCs Accumulate Smo in the PC without Activating the
Hh Pathway
To investigate in more detail the consequences of GC-induced
Smo accumulation in the PC, and to obtain mechanistic insights
into GC action in the Hh pathway, we first chose one compound
in clinical use, fluocinolone acetonide (FA). FA displays an EC50
of around 5 mM for accumulation of Smo in the PC; in addition,
no obvious cytotoxic effects are observed in vitro at much higher
doses (up to 200 mM; Figures 1B and 1D; Figure S1M). Localiza-
tion of an inversin-based PC reporter and other PC markers
including Arl13b, acetylated tubulin, and detyrosinated a-tubulin
(glu-tub) were unaltered in response to FA (Figure 1D; Figures
S1M and S1N) (Caspary et al., 2007; Schrøder et al., 2007; Wa-
tanabe et al., 2003). Further, no change was detected in the
activity of a Wnt-signaling reporter in response to FA concentra-
tions that modify Smo distribution (Figure S1O). Together, these
data suggest that FA’s effects in this assay are specific to the Hh
pathway.2–982, August 24, 2012 ª2012 Elsevier Ltd All rights reserved 973
Figure 1. Glucocorticoids Induce Smo Accumulation at the Primary Cilium
(A) Structures of ten representative naturally occurring and synthetic GCs (names in bold).
(B) Related dose-response curves for accumulation of Smo in the PC using the subset of GCs indicated in (A). The mean (± SD) was calculated for four replicates
analyzing several hundred cells in each sample.
(C) Key positions correlating with Smo accumulation activity in the GC scaffold are highlighted in red.
(D) Representative images of dose-dependent accumulation of Smo at the PC in response to stimulation by a synthetic GC, fluocinolone acetonide (FA). Scale
bar: 10 mm.
See also Figures S1 and S4.
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for transcriptional activation of the Hh pathway (Kim et al., 2009;
Rohatgi et al., 2007). However, we observed a marked disparity
between FA-induced Smo accumulation in the PC and Hh
pathway activation in transcription reporter assays. At low levels
of FA that effectively promote Smo accumulation in the PC
(10 mM), no pathway activation was observed. Higher concentra-
tions (>50 mM) invoked a weak transcriptional response measur-
able in a Gli-luciferase reporter assay (4-fold versus 25-fold for
1 mM of the Smo agonist SAG in the same assay [data not
shown]), and on quantitative reverse transcription (qRT)-PCR
measurement of Hedgehog target gene expression (Ptch1 and
Gli1; Figures 2A and 2B). The EC50 for weak transcriptional acti-
vation (>50 mM)was 10-fold higher than that of FA-induced accu-
mulation of Smo within the PC.
FA Induces Hypersensitivity to Hh Pathway Stimulation
The effects of FA resemble overexpression of Smo in that consti-
tutive accumulation of wild-type Smo within the PC only results
in weak pathway activation (Figure S2A). Ciliary accumulation
of Smo sensitizes cells to subsequent Sonic hedgehog (Shh)
ligand input, raising the possibility that FA-driven Smo accumu-
lation may sensitize Hh-responsive cells. Indeed, costimulation
of cells with 10 mMFA results in a dose-dependent enhancement
of a Shh-induced transcriptional response (Figures 2C and 2D).
Furthermore, this effect was measurable after prolonged with-974 Chemistry & Biology 19, 972–982, August 24, 2012 ª2012 Elsevidrawal of FA; cells treated for 24 hr with FA followed by com-
pound withdrawal prior to Shh addition showed a higher induc-
tion of pathway activity than DMSO-treated controls (Figures
2E and 2F). The EC50 of a FA-induced response to priming is
approximately 4 mM, in good agreement with the dose required
for efficient accumulation of Smo in the PC (Figure 1B). Smo turn-
over in the PC is relatively slow after Shh-invoked pathway acti-
vation (Wang et al., 2009), or compoundwithdrawal (Figures S2B
and S2C), providing a potential explanation for a FA-induced
pathway priming effect. FA treatment showed no effect on Wnt
pathway activity (Figure S1O), consistent with Hh pathway
specificity.
FA May Regulate Smo by Direct Binding
To determine whether FA interacts with Smo, we performed
a competition assay with Bodipy-Cyc. Cyc binds Smo directly
(Chen et al., 2002a) and its fluorescent analog, Bodipy-Cyc,
shows strong Smo-dependent fluorescence within cells over-
producing Smo (identified by coexpression of a nuclear localized
tagRFP-T; Figures 2G and 2H). An oncogenic mutation within the
seventh transmembrane domain (SmoM2, also named SmoA1;
Figures 2H and 2I) (Chen et al., 2002a), and a recently described
drug resistance mutation within the sixth transmembrane
domain (SMOD473H) significantly impair Cyc binding to Smo,
suggesting that these are critical sites for chemical interaction
(Yauch et al., 2009).er Ltd All rights reserved
Figure 2. FA Sensitizes Cells to Hh Stimula-
tion and Competes with Cyc Binding to Smo
(A) Modest but significant activation of the Hh
pathway at high doses of FA, measured by a Gli-
responsive luciferase reporter activity in NIH/3T3
cells. FA action is blocked by Smo antagonists
SANT-1 and Cyc. *p < 0.0001 (t test), comparing
with DMSO, FA+SANT-1, or FA+Cyc.
(B) FA upregulates the expression of Hh target
genes Ptch1 and Gli1 in NIH/3T3 cells. #p < 0.02
(t test).
(C and D) Measurement of Hh pathway activity in
cells treated simultaneously with a fixed concen-
tration of FA and different concentrations of Shh
ligand (C), or with a fixed concentration of Shh
ligand, and different concentrations of FA (D).
Treatment with Shh ligand and DMSO were used
for comparison.
(E) Measurement of Hh pathway activity after
stimulation with various concentrations of Shh
ligand following priming treatments with 10 mM FA
(red curve). DMSO prime treatments (blue curve)
were used for comparison.
(F) Measurement of Hh pathway activity after
stimulation with a fixed dose of Shh ligand fol-
lowing priming treatments with different concen-
trations of FA (red curve) or when pathway activity
was stimulated by expressing a constitutively
active SmoM2 variant (blue curve). All Gli-lucif-
erase assay samples were replicated four times.
The qRT-PCR in (B) was performed in triplicate.
Data represent mean (± SD).
(G) Schematics showing the structures of Bodipy-
Cyc and Smo. Critical sites in the sixth and
seventh transmembrane domains of Smo, that are
likely important for direct interactions are high-
lighted by a rectangle.
(H) Representative merged images from Bodipy-
Cyc competition assays. Transfected cells can be
identified by colabeling with nuclear localized
tagRFPT.
(I) Quantification of Bodipy-Cyc fluorescence
signal: each data point represents values from 50
to 100 transfected cells. The controls, including
data from a parental plasmid (pCIT), Smo and
SmoM2 expressing cells were displayed as the
dashed lines. Mean (± SD) was calculated from
four replicate samples. Scale bar: 10 mm.
See also Figures S2 and S4.
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binding to wild-type Smo, similar to other small molecules that
directly bind Smo (SAG, and GDC0449), or that likely interact
directly with Smo based on similar competition assays (SANT-
1) (Figures 2H and 2I) (Chen et al., 2002a, 2002b; Frank-Kame-
netsky et al., 2002; Yauch et al., 2009). In contrast, FKL induces
Smo accumulation in the PC but does not compete with Bodipy-
Cyc, reflecting an indirect action through its protein kinase A
target (Milenkovic et al., 2009; Wilson et al., 2009). Weak
pathway activation induced by FA was attenuated by Smo
antagonists (Figure 2A) and depended on endogenous Smo as
activation was not observed in fibroblasts lacking Smo activity
(Figure S2D). SANT-1 and GDC0449 inhibit FA promoted accu-Chemistry & Biology 19, 97mulation of Smo in the PC (Figures S2E and S2F). Collectively,
these data support a direct interaction between FA and Smo.
Antagonistic Drug-Drug Interactions between FA and
Smo Antagonists
Considering that GCs and various Hh pathway antagonists may
share a common Smo target, and GCs are widely used to
suppress inflammation in conjunction with cancer therapy, we
next asked whether we could observe a potential GC crosstalk
with Smo antagonists in cell culture assays. Hh pathway inhibi-
tion by GDC0449, Cyc and SANT-1, as measured by both Gli-
luciferase induction (Figure 3A; Figure S3) and Smo ciliary local-
ization (Figures 3B and 3C; Figure S3), was dramatically reduced2–982, August 24, 2012 ª2012 Elsevier Ltd All rights reserved 975
Figure 3. Drug-Drug Interaction between FA and GDC0449
(A) GDC0449 dose-dependent inhibition of Shh-stimulated Hh pathway activity in the presence or absence of 10 mM FA, or SmoM2 expressing cell lines.
(B) Representative images of Smo::EGFP/Ivs::tagRFPT cells treated with GDC0449 and Shh in the presence or absence of 10 mMFA. GDC0449 was coapplied at
111 and 1,111 nM respectively with Shh and Shh+FA.
(C) Relative Smo::EGFP+ cilium count of GDC0449’s dose-dependent inhibition of Shh ligand-stimulated accumulation of ciliary Smo in the presence or absence
of 10 mMFA. Measurements were performed in quadruplicate. Several hundred cells were analyzed in each sample to assess the accumulation of Smo in the PC
from data in (B). Data plotted are mean (± SD). Scale bar: 5 mm.
See also Figures S3 and S4.
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a drug-dependent alteration of cellular response to chemical
inhibitors of Smo. This may occur through competition, or the
requirement for a higher level of GDC-0449 to inhibit Hh-driven
pathway activity in the presence of GC, but the outcome resem-
bles the genetic resistance seen with a dominant active Smo
mutation (SmoM2) (Figure 3A).
Common Properties of FA and TA in Modulating Smo
Localization and Hh Pathway Activity
We next assessed whether the observations for FA were repli-
cated by a second clinically approved GC, triamcinolone aceto-
nide (TA). TA was slightly more potent than FA in Smo ciliary
translocation assay (Figure 1B). Similar to FA, TA only evoked
a Gli-mediated transcriptional response at much higher doses
than those that induced Smo ciliary accumulation, although the
Hh pathway was activated to higher levels than measured on
FA treatment (Figure S4A). No activation was observed in
Smo/ embryonic fibroblast cells as expected (Figure S2D).
Further, at 10 mM TA enhanced the response to Hh ligand
(Figure S4B), a dose that does not sufficient to induce ligand-
independent pathway activity (Figure S4A). TA also displayed
a dose-dependent competition with Bodipy-Cyc for binding to
Smo (Figures S4C and S4D). More importantly, 10 mM TA in-
duced a dose-response shift for GDC0449 mediated inhibition
of Hh pathway activity, and Smo ciliary accumulation induced
by ligand treatment (Figures S4E–S4G). Taken together, our
results indicate that these, and possibly other GCs that alter
Smo localization share broadly similar biological properties but
further work will be required to examine the extensive set of
compounds identified in our study.
Ex Vivo Studies of FA with Ptch1+/– CGNPs
To further explore FA actions, we isolated cerebellar granule
neuron precursors (CGNPs) from Ptch1+/ neonates. Prolifera-
tion of CGNP is Shh-dependent and Ptch1 heterozygosity
predisposes both mice and humans to develop CGNP-derived976 Chemistry & Biology 19, 972–982, August 24, 2012 ª2012 Elsevimedulloblastoma (Schu¨ller et al., 2008). Consistent with results
on Hh pathway activation in NIH 3T3 cells, only very high doses
of FA (120 mM) elevated the number of proliferative, phosphohi-
stone H3 (pH3) positive CGNPs (Figures 4A and 4B). However,
a lower dose of FA (10 mM) markedly enhanced Shh-driven
CGNP proliferation (Figures 4C and 4D). Further, coadminis-
tration of FA (10 mM), with the Smo antagonist GDC0449, im-
paired GDC0449 inhibition of Shh-stimulated CGNP proliferation
(Figures 4E and 4F).
GC Inhibitors of Smo Accumulation to the PC and of Smo
Signaling
While a large number of GCs promote Smo ciliary accumulation,
secondary assays of small molecules sharing the core GC scaf-
fold identified two inhibitory GCs: budesonide (Bud) and cicleso-
nide (Cic) (Figures 5A–5C; Figures S5A–S5C). When compared
with Smo promoting GCs, Bud and Cic are distinguished by
bulky hydrophobic groups at positions 16 and 17 (Figure 1; Fig-
ure S1L; Figure 5A; Figure S5A). In contrast to FA and TA, Bud
hadnopathway inducing activity, nor didBud induce ahypersen-
sitive response to Hh ligand (Figures 2A–2F and 5D), reinforcing
the association of hyperresponsiveness to Smo ciliary accumu-
lation activity. As expected from the inhibition of Smo accumula-
tion in the PC, Bud andCic inhibited Shh-dependent activation of
a Gli reporter (Figure 5E; Figure S5D). Further, Bud attenuated
Smo ciliary accumulation and pathway activation by SAG (Fig-
ure 5E; Figures S5E and S5F), and also suppressed Cyc-induced
Smo accumulation to the PC (Figures S5E and S5F). Bud treat-
ment showed no effect on Wnt pathway activity (Figure S5G),
consistent with a specific modulation of Hh signaling outside of
its GC activity.
Bud Inhibit Ciliary Localization and Signaling of Drug-
Resistant Mutants of Smo
SmoM2 encodes a dominant active Smo variant identified
in a human cancer that is resistant to inhibition by available
Smo antagonists at concentrations that completely suppresseder Ltd All rights reserved
Figure 4. FA Modulates Proliferation of
Cerebellar Granule Neural Precursors
CGNP proliferation was quantified based on
percentage of pH3 positive cells. Representative
images and measurements were shown for FA
dose-dependent modulation of CGNP prolifera-
tion (A and B), promotion of Shh-stimulated CGNP
proliferation by 10 mMFA (C and D), and GDC0449
dose-dependent inhibition of Shh-stimulated
CGNP proliferation in the presence or absence of
10 mM FA (E and F). GDC0449 was applied at
100 nM in (E). Mean (± SD) was calculated from
four replicate samples each containing over a
thousand cells. *p = 0.0003(t test). #p < 0.0001
(t test). Scale bar: 20 mm.
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Unexpectedly, both Bud and Cic attenuated SmoM2 ciliary
localization, and downstream pathway activity, as effectively
as wild-type Smo (Figures 5F–5H; Figures S5L and S5M). Bud
and Cic did not disrupt ciliary structure or ciliary trafficking: acet-
ylated-tubulin (acet-tub), Ivs::tagRFPT, and Arl13b::tagRFPT
within the PC were unaltered on treatment (Figures S5N–S5R).
The emergence of a drug-resistant form of Smo with a D473H
mutation was reported in a MB patient during treatment with
GDC0449. The appearance of this mutation associated with a
re-emergence of the tumor (Yauch et al., 2009). This finding has
triggered a search for antagonists that effectively inhibit the
activity of both wild-type and mutant forms of Smo (Dijkgraaf
et al., 2011; Kim et al., 2010; Tao et al., 2011). We examined
Bud and GDC0449 in parallel for their inhibition of Hh-induced
SmoD473H activity, and the corresponding ciliary localization.
Smo/ MEF cells were transfected independently with wild-
type and D473H mutant forms of Smo. Both forms rescued the
cell’s response to Hh ligand (Figure S5S). As expected, the
D473H mutation conferred a dramatic resistance to GDC0449’s
inhibitory action on both Hh pathway activity and Smo ciliary
localization (Figures S5T–S5V). In contrast, Bud showed similar
efficacies in inhibiting wild-type Smo and SmoD473H activity in
both assays (Figures 5I–5K).
To investigate the site of Bud action in the Hh pathway, we
examined Hh signaling activity following removal of suppressor
of Fused (suFU) activity, a Gli repressor functioning downstream
of Smo. Distinct from GANT61 (Lauth et al., 2007), Bud failed
to suppress ligand-independent Hh pathway activity inducedChemistry & Biology 19, 972–982, August 24, 2012by loss of suFU function (Figure 5L).
Together these data suggest that Bud
may act at the level of Smo but
through a different mechanism than other
Smo-interacting antagonists including
SANT-1, Cyc, and GDC0449, and also
distinct from FA and SAG. Consistent
with a unique inhibitory action, Bud failed
to compete with Bodipy-Cyc even at
levels well above the inhibitory maximum
(100 mM; Figures 5M and 5N). Further,
whereas FA competed with GDC0449
to suppress effective pathway inhibition
(Figure 3), Bud enhanced GDC0449’s ac-tivity to block Smo accumulation at the PC and Hh pathway
inhibition (Figure 6).
DISCUSSION
The interaction of GCs with the Hh pathway leads to several
important observations. First, all small molecules that induce
ligand-independent Smo accumulation to the PC character-
ized to date either activate or inhibit Smo activity. Agonists
include SAG and purmorphamine (Chen et al., 2002b; Frank-Ka-
menetsky et al., 2002; Sinha and Chen, 2006). Cyc though an
antagonist also induces Smo translocation to the PC (Rohatgi
et al., 2009; Wang et al., 2009; Wilson et al., 2009). Several lines
of evidence indicate that whereas Smo accumulation in the
PC is essential for signaling, accumulation is not sufficient,
with additional ligand-dependent actions being required to
generate an active form of Smo (Rohatgi et al., 2009; Wang
et al., 2009; Wilson et al., 2009). Together, our data suggest
that many GCs can function in a novel mechanism that syner-
gizes with Hh-ligand-directed signaling by promoting accumula-
tion of Smo within the PC. The synergistic effect might result
from bypassing a Ptch1-mediated ‘‘barrier’’ for Smo entry to
the PC facilitating the activation of Smo, which appears to be
restricted to this organelle. The mechanism of divergent phar-
macological modulations of Smo ciliary translocation and its
activity is not understood. A recent report suggested that Smo
phosphorylation plays a role in its ciliary translocation and acti-
vation (Chen et al., 2011). Further study of small molecule
directed changes in Smo phosphorylation will enhance ourª2012 Elsevier Ltd All rights reserved 977
Figure 5. Bud Inhibits Hh Pathway Activity Induced by Various Stimuli and Does Not Compete with Cyc for Binding Smo
(A) The chemical structure of Bud.
(B andC) representative images (B) and quantification of Smo ciliary localization (C) in Smo::EGFP/Ivs::tagRFPT cells treatedwith Shh and varying concentrations
of Bud.
(D) Measurement of Hh pathway activity in cells treated with Bud only or Bud followed by Shh.
(E) Dose-dependent inhibition of Hh pathway activity by Bud on Shh or SAG treatment, 50 nM or 1 mM, respectively.
(F and G) representative images (F) and quantification of Smo::EGFP or SmoM2::EGFP ciliary intensity (G) from cells treated with Bud. Bud was used at 22.2 mM
in (F).
(H) Bud’s dose-dependent inhibition of Hh pathway activity induced by overexpression of wild-type Smo and SmoM2 respectively.
(I) Bud’s dose-dependent inhibition of Hh pathway activity induced by Shh ligand in Smo/ cells transfected with constructs expressing wild-type Smo and
SmoD473H, respectively.
(J and K) representative images (J) and quantification of Smo::EGFP or SmoD473H::EGFP ciliary intensity (K) from cells treated with Bud.
(L) Measurement of Hh pathway activity in suFU/ cells treated with Bud and FA, respectively. DMSO and SAGwere used as negative controls and GANT61 was
a positive control.
(M and N) representative images (M) and quantification of Bodipy-Cyc intensity in Smo-expressing cos7 cells (N) treated with Bodipy-Cyc and Bud. Vehicle was
used for comparison. Budwas used at 200 mM in (M). All quantitative data represent mean (± SD) from either quadruplicated samples (imaging assays) or triplicate
experiments (Gli-luciferase assays). Quantifications of ciliary localization involved over a thousand cells per sample whereas 50–100 Smo expressing cells were
analyzed in each treatment for Bodipy-Cyc competition assay. Scale bar: 5 mm.
See also Figure S5.
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tion and activity.
Second, the finding of a potential effect of Smo promoting
GCs in modulating the Hh response highlights the value of
a ‘‘direct target screen’’ focusing on critical parameters of target
action. To date, most small molecule Hh pathway modulators
have been identified through ‘‘end-point’’ transcriptional assays.
However, because of their modest effects on transcription,
GC interactions are not readily detected with this screening978 Chemistry & Biology 19, 972–982, August 24, 2012 ª2012 Elseviapproach. Such disparity suggests that the mechanism of
pharmacological induction of Smo accumulation to the primary
cilium and its retention there is divergent from that of its
activation.
Third, the dose of GC required to modify Smo localization
(EC50s > 1 mM) is significantly higher than that required to directly
modulate GC receptor-based transcriptional responses [EC50s <
10 nM or lower (Johnson, 1998)]. Thus, we believe GCs likely
act directly on Smo at high concentrations, and not indirectlyer Ltd All rights reserved
Figure 6. GDC0449 and Bud Combinatorially Inhibit Smo-Directed Hedgehog Signaling
(A and B) Quantification of Smo ciliary localization (A) and representative images (B) of Smo::EGFP/Ivs::tagRFPT cells treated with GDC0449 and Shh in the
presence or absence of 10 mM Bud. In (B), GDC0449 was coapplied at 1.6 nM with Shh and Shh+Bud, respectively.
(C) GDC0449 dose-dependent inhibition of Shh-stimulated Hh pathway activity in the presence or absence of 10 mMBud. Data plotted are mean (± SD) from four
biological replicates (A) analyzing over a thousand of cells or three biological replicates (C). Scale bar: 5 mm.
Chemistry & Biology
Glucocorticoid Crosstalk with Hedgehog Signalingthrough a nuclear hormone receptor triggered transcriptional
regulatory action.
Fourth, naturally occurring hydrocortisone and cortisone show
different potencies in accumulating Smo to the PC (Figures 1A
and 1B). 11b-hydroxysteroid dehydrogenase type 2 (HSD11b2),
anenzyme that transformshydrocortisone into cortisone, is upre-
gulated by Hh signaling in CGNPs (Heine and Rowitch, 2009),
whereas HSD11b1, an enzyme that mainly catalyzes the reverse
reaction, was recently discovered as a target gene for Hh signal-
ing in prostate cancer tissue (Shaw et al., 2009). Taken together,
these findings suggest potential feedback mechanisms linking
the Hh transcriptional output to steroid regulation of Smo action.
Fifth, inflammation and cancer are linked, necessitating com-
binatorial therapies to treat both aspects of disease (Mantovani
et al., 2008). To this end, GCs are frequently coadministered to
patients receiving anticancer therapies. However, GCs are re-
ported to enhance cancers of the breast (Sui et al., 2006), colon
(Zhang et al., 2006a), lung (Herr et al., 2003), ovary (Sui et al.,
2006; Zhang et al., 2006b), and pancreas (Zhang et al., 2006c),
and to increase the metastatic potential of breast cancer (Sher-
lock and Hartmann, 1962). Among these are glucocorticoids that
promote Smo ciliary accumulation in the current study. Further,
FA is reported to act as a tumor promoter in the skin (Fukao
et al., 1988). Our studies also raise the possibility of high dosing
of glucocorticoids leading to off-target action of glucocorticoid
agents in the Hh pathway, modifying therapeutic outcome: for
example, in Hh antagonist-directed cancer therapy. Whether
an effective dose for GC drug-mediated crosstalk is reached
during therapeutic administration is not clear, but the pharmaco-
kinetics of certain GC drugs in human patients may warrant
further investigation. For example, a peak plasma concentration
of Dexamethasone, a broadly used GC in cancer patients, has
been reported at >10 mM after a single high dose (Brady et al.,
1987), which falls in the range where significant Smo cilial accu-
mulation occurs in vitro (data not shown). Long-term systematic
treatment, common in cancer therapy, might result in longer
exposure to higher concentrations. Further, high dose of gluco-
corticoids are given to preterm infants to accelerate maturation
of the lungs. Whether glucocorticoids in this scenario may influ-
ence developmental Hh signaling is not known.Chemistry & Biology 19, 97Sixth, our data suggest that most GCs likely share a similar
interaction site with a broad range of agonists and antagonists
including SAG, GDC0449, SANT-1, and Cyc, or modify Smo on
binding to block access to this binding region. In contrast,
Bud-like GCs do not compete with other Smo antagonists.
Further, Bud works equally well inhibiting wild-type Smo and
mutant forms of Smo refractory to clinically active inhibitory
compounds. Thus, it may act more like an allosteric regulator
of Smo activity. Interestingly, GDC0449-resistant SmoD473H
can be readily inhibited by its related benzimidazole HhAntag
(Dijkgraaf et al., 2011). Subsequent efforts to improve Bud
potency should keep in mind the clinical imperative of pan-inhi-
bition of Smo mutant forms. Collectively, our findings highlight
the potential to develop new drugs around a GC scaffold that
may synergize with compounds currently undergoing clinical
development to enhance anti-Hh-based cancer therapies and
may also reveal more about the ways in which Smo trafficking
and activity are regulated.
SIGNIFICANCE
For some time, the hedgehog pathway has been recognized
as a key regulator of embryonic development and, as such,
has been implicated in a variety of birth defects. However,
especially over the past decade, this pathway has been
shown to participate directly or indirectly in the growth of
various types of solid tumors, including basal cell carcinoma
andmedulloblastoma, and bloodmalignancies. As such, the
pathway has been targeted by an ever-larger number of
pharmaceutical companies, with Vismodegib, developed
by Genentech and Curis, being the first hedgehog inhibitor
approved by the FDA. For work described in this paper,
we established an image-based screen in which we mea-
sured the translocation of the key signaling protein, Smooth-
ened, from the cytoplasm to the primary cilium. Smoothened
is the target of Vismodegib and of many of the other inhibi-
tors being developed, and its translocation is one of the
key events in propagating a hedgehog signal from the mem-
brane to the nucleus. Interestingly, functional antagonists
may either stimulate (cyclopamine) or inhibit (Vismodegib)2–982, August 24, 2012 ª2012 Elsevier Ltd All rights reserved 979
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signaling than had been realized initially. We found that
various types of glucocorticoids, when used at relatively
high concentrations, can act as Smoothened modulators.
One class, represented by fluocinolone acetonide and triam-
cinolone acetonide, appears to bind to Smoothened, stimu-
late its cilial localization and can enhance hedgehog
signaling. Another chemically related class, represented by
budesonide, may bind to a different site on Smoothened,
inhibits Smoothened translocation and blocks hedgehog
pathway activity. Budesonide has another interesting prop-
erty—not shared by Vismodegib—of inhibiting different
mutated forms of Smoothened, including one that has been
shown to arise in patients with medulloblastoma. It appears
that additional small molecule focused probing of the
hedgehog pathway may provide, in the future, even more
useful information and, perhaps, a few surprises.
EXPERIMENTAL PROCEDURES
Cell Culture
NIH/3T3 cells weremaintained in DMEMcontaining 10% (v/v) calf serum, peni-
cillin, streptomycin, and L-glutamine. HEK293, L, cos7, and suFU/ mouse
embryonic fibroblast cells weremaintained in DMEMcontaining 10% (v/v) fetal
bovine serum, penicillin, streptomycin, and L-glutamine. Smo::EGFP and
Ivs:: tagRFPT were cloned into pBabe retroviral constructs. Smo::EGFP/
Ivs::tagRFPT stable cell lines was generated through viral infecting NIH/3T3
cells according to the procedure described previously (Wang et al., 2009). A
ShhLightII cell line (ATCC) was used for Gli-luciferase reporter assays. This
line contains a stably integrated Gli-responsive firefly luciferase reporter and
a constitutive Renilla luciferase expression construct (Taipale et al., 2000). A
subclone of this cell line was created expressing a stably integrated SmoM2
expression construct. Shh conditioned medium was collected from cos7 cells
transfected with an expression construct encoding the amino terminal 19 kDa
signaling peptide of Shh and used at 13.7 (± 3.0) nM unless stated otherwise.
Control conditionedmediumwas collected from cos7 cells transfected with an
empty plasmid. Wnt3a conditioned medium was collected from an L cell line
stably expressing aWnt3a expression construct. Control-conditionedmedium
was collected fromwild-type L cells. All conditionedmediumwere diluted 1:10
prior to assay.
Reagents
Chemical libraries screening utilized the Library of Pharmacologically Active
Compounds (LOPAC, Sigma-Aldrich), the Spectrum Collection (Microsource
Discovery Systems), and the Prestwick Chemical Library (Prestwick Chemi-
cal), along with a custom collection of additional biologically annotated
chemistries absent from the above pre-plated reference collections. Glucocor-
ticoids, cyclopamine, forskolin, mouse monoclonal antiacetylated tubulin
antibody for follow-up studies were purchased from Sigma. SAG was
purchased from Axxora Platform. SANT-1 was obtained from Tocris Biosci-
ences. GDC0449 was purchased from Selleck Chemicals. BODIPY-cyclop-
amine was purchased from Toronto Research Chemicals. All small molecule
stock solutions were prepared by dissolving in DMSO at 1 or 10 mM and
stored at 20C. Mouse recombinant ShhN purified protein (IIShhN) was
a gift from Dr. Pepinsky (Biogen Inc). Rabbit polyclonal antidetyrosinated
a-tubulin (Glu-tub) was from Chemicon, Mouse monoclonal anti-Arl13b
antibody was from Antibody Incorporated. Secondary antibodies were from
Life Technologies. Transfection was performed using Fugene6 or Fugene
HD (Roche).
Imaging Assays
Cells were cultured and treated in 384-well imaging plate precoated with
poly-D-Lysine (Greiner Bio-one), fixed with 4% paraformaldehyde (Electron
Microscopy Sciences), and stained with Hoechst (Life Technologies). Immu-
nofluorescence staining was conducted with standard procedures when980 Chemistry & Biology 19, 972–982, August 24, 2012 ª2012 Elsevinecessary. Images were collected using Opera High Content Screening
System (PerkinElmer). ActivityBase (IDBS), Pipeline Pilot (Accelrys), Excel
(Microsoft), and Prism (GraphPad) were used for high content screening
data management and analysis. Acapella 2.0 software (Evotec Technolo-
gies/PerkinElmer) was used to perform multiparametric image quantification.
All the comparative images were scanned with identical microscopic setting
and analyzed with the same input parameters.
Hh and Wnt Activity Assays
ShhLightII cells and SmoM2/LightII cells were cultured and treated in 96-well
assay plates (Corning) and incubated with Duo-Glo luciferase substrates
(Promega) to sequentially measure firefly and renilla luciferase activity. Smo,
or GFP, expression plasmids were cotransfected into 3T3 cells together with
a Gli-responsive firefly reporter and a TK-renilla luciferase reporter construct
to monitor effects of Smo overexpression. Cotransfection of the two reporter
constructs was conducted in assays measuring Hh pathway activity in
suFU/ cells. Wnt activity was measured following cotransfection of a Top-
flash and renilla luciferase reporter. In both Hh and Wnt activity assays, renilla
luciferase reporter activity, or mass of protein, was used to normalize expres-
sion values. Luciferase signal was read by TopCount NX Microplate Scintilla-
tion and Luminescence Counter (PerkinElmer). Quantitative PCR probes for
Ptch1, Gli1, and b-actin were purchased from Applied Biosystems. Reactions
and measurements were performed using on an Applied Biosystems 7900HT
at Harvard FASCenter of SystemBiology. b-actinwas used to normalizePtch1
and Gli1 values.
Bodipy-Cyclopamine Competition Assays
Cos7 cells were transfected with a plasmid that coexpresses Smo and
a nuclear localized tagRFPTmarker (pCIT-Smo). The empty parental construct
(pCIT) and a construct that coexpress SmoM2were used as controls to assess
specificity and background signal. Three days after transfection, cells were
incubated with 5 nM Bodipy-cyclopamine, with or without additional com-
pounds, for 1 hr at 37C. Cells were then fixed and stained with Hoechst.
Images were collected with the Opera High Content Screen System. Fluores-
cence values were assessed in transfected cells (red nuclei) with a program
developed by the authors using Acapella 2.0 software. All of images were
scanned with identical microscopic setting and analyzed with the same input
parameters.
CGNP Proliferation Assays
CGNP primary cells were isolated from P7 Ptch1+/ mice as previously re-
ported (Chan et al., 2009). Cells were seeded in poly-D-lysine coated imaging
plates (Greiner Bio-one), treatments were applied 2 hr thereafter and last for
36 hr. Cells then were fixed with 4% paraformaldehyde (Electron Microscopy
Sciences), and stained with anti-pH3 antibody (Upstate; 1:100) followed by
a secondary antibody (Invitrogen) and Hoechst (Invitrogen). Images were
collected and cell proliferation quantified with a program developed by the
authors utilizing Acapella 2.0 software. All of the images in each experiment
were collected with identical microscopic settings and analyzed with identical
input parameters.
SUPPLEMENTAL INFORMATION
Supplemental Information includes five figures and can be found with this
article online at http://dx.doi.org/10.1016/j.chembiol.2012.06.012.
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